首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   31篇
  免费   2篇
儿科学   3篇
基础医学   3篇
临床医学   2篇
内科学   16篇
神经病学   2篇
外科学   1篇
预防医学   3篇
药学   3篇
  2007年   1篇
  1999年   1篇
  1992年   1篇
  1991年   1篇
  1990年   2篇
  1989年   1篇
  1988年   1篇
  1987年   2篇
  1986年   3篇
  1985年   1篇
  1984年   3篇
  1983年   3篇
  1982年   3篇
  1981年   1篇
  1979年   2篇
  1978年   1篇
  1977年   1篇
  1975年   1篇
  1973年   1篇
  1969年   1篇
  1957年   2篇
排序方式: 共有33条查询结果,搜索用时 15 毫秒
1.
In vivo studies of intestinal carnitine absorption in rats   总被引:2,自引:0,他引:2  
We have studied small intestinal absorption of carnitine in vivo using a combination of segmental perfusion techniques and bolus intraluminal injection. We found evidence of a partially saturable absorption process (with Km values of 1035 and 1267 microM for jejunum and ileum calculated for the saturable component) that appeared to be separate from the imino acid transport system. Absorption was characterized by slow mucosal uptake, prolonged mucosal retention, and a very slow mucosal exit process with blood levels of [3H] carnitine still rising 8 h after intraluminal administration. We have also demonstrated the presence of carnitine acetyltransferase in intestinal mucosa and have shown that the intestine forms significant amounts of acetylcarnitine from exogenous carnitine.  相似文献   
2.
3.
Summary The metabolic and physiologic differences between low-flow and zero-flow ischemia of varying duration were compared in the isolated perfused rat heart. Hearts subjected to 60 and 90 minutes of zero-flow ischemia recovered less cardiac work than hearts subjected to low-flow ischemia. Low-flow ischemia caused a build-up of both myocardial long-chain acyl coenzyme A and acyl carnitine esters, while zero-flow ischemia produced no change in long-chain acyl carnitine and only a transient increase in long-chain acyl coenzyme A. High energy phosphate depletion was greater in zero-flow ischemia. Perfusion with excess free fatty acids decreased the recovery of cardiac work after low-flow ischemia but had no effect after repeated episodes of zero-flow ischemia. L-Acetylcarnitine improved the recovery of cardiac work after low-flow ischemia in hearts perfused with 0.4 and 1.2 mM palmitate. With zero-flow ischemia, L-acetylcarnitine had no effect on the recovery of cardiac work in hearts perfused with 0.4 mM palmitate and a slight but statistically significant effect with 1.2 mM palmitate. Possible protective mechanisms of L-acetylcarnitine against ischemic damage are discussed.  相似文献   
4.
5.
Results from this study indicate that caffeine (at an embryotoxic dose equal to the LD40 administered to 3-day chick embryos produced both ultrastructural and functional abnormalities in embryonic cardiac mitochondria. The principal effects of caffeine on the ultrastructure of embryonic myocardial cells were clearly suggestive of cellular injury and included: (1) a marked disruption of mitochondrial cristae with formation of intramitochondrial myelin-like figures and (2) intracellular edema. A biochemical analysis of mitochondrial function revealed that caffeine inhibited the capacity of mitochondria to oxidize succinate. However, when pyruvate and malate were employed as substrates for isolated mitochondria, caffeine did not significantly alter mitochondrial function. Interference with embryonic cardiac mitochondrial succinate oxidation and/or fragmentation of mitochondrial membranes are suggested as possible events in the pathogenesis of caffeine-induced cardiac cell injury which, in turn, may lead to the embryonic death of the chick.  相似文献   
6.
Zusammenfassung In diesem Bericht werden 2 Familien vorgestellt, in denen kindlicher Carnitin-Mangel zu Kardiomyopathien führte, die in einem Fall erfolgreich behandelt werden konnten. Symptomatik, Diagnose und Therapie des Carnitin-Mangels werden gemeinsam mit seinen biochemischen Grundlagen diskutiert.Carnitin (CAR), eine 4wertige Ammoniumverbindung, die im Körper aus den Aminosäuren Lysin und Methinonin synthetisiert wird, spielt eine wichtige Rolle in der Fettsäureoxidation. CAR dient als Carrier für den Transport langkettiger Fettsäure-CoA-Ester aus dem Cytoplasma in die Mitochondrien. Daher führt Car-Mangel zu Störungen der mitochondrialen Fettsäureoxidation und der Akkumulation von Lipiden im Cytoplasma. Besonders betroffen ist das Herz, das zur Deckung seines Energiebedarfs in großem Umfang von der Fettsäure-Oxidation abhängig ist.CAR-Mangel kann, je nach dem zugrundeliegenden biochemischen Defekt, in verschiedenen Formen auftreten. Systemischer CAR-Mangel wurde in einer Familie entdeckt, in der 4 von 5 Kindern Kardiomyopathien entwickelten und 3 Kinder vor dem Alter von 3 Jahren plötzlich verstarben. Bei der Autopsie wurde die klinische Diagnose einer Kardiomyopathie in allen Fällen bestätigt. Bei der Autopsie des 5, und jüngsten Kindes wurden außerdem Lipidakkumulation und abnorme Mitochondrien im Herz- und Skelettmuskel nachgewiesen, zusammen mit extrem niedrigen CAR-Spiegeln im Plasma (4,5 mM; normal 50±10 mM), im Skelettmuskel (30,9 nmol/g; normal 5000 nmol/g) und Myokard (56,8 nmol/g; normal 2000 nmol/g). Das überlebende 4. Kind hatte ebenfalls eine schwere congestive Kardiomyopathie und Herzinsuffizienz (NYHA III). Plasma (4,8 mM)-, und Muskel (30,9 nmol/g)-CAR-Spiegel waren extrem niedrig. Durch orale Substitutionstherapie mit L-CAR konnte eine dramatische klinische Besserung erreicht werden. Plasma- und Muskel-CAR-Spiegel stiegen, und die Muskelhistologie besserte sich.Wir schließen aus diesem Verlauf, daß es das Krankheitsbild einer kindlichen Kardiomyopathie, die durch Carnitin-Mangel hervorgerufen wird, gibt. Diese Kardiomyopathie ist durch Lipidakkumulation gekennzeichnet und spricht gut auf CAR-Substitution an. Wir glauben, daß bei allen familiär auftretenden Kardiomyopathien unklarer Genese, besonders wenn Lipidakkumulation nachgewiesen ist, der Plasma-Carnitin-Spiegel gemessen und nötigenfalls eine Substitutionstherapie mit L-Carnitin eingeleitet werden sollte.  相似文献   
7.
8.
OBJECTIVES: L-carnitine and dehydro-epiandrosterone (DHEA) independently promote mitochondrial energy metabolism. We therefore wondered if an age-related deficiency of L-carnitine or DHEA may account for the declining energy metabolism associated with age. METHODS: we evaluated serum levels of L-carnitine and the sulphated derivative of DHEA (DHEAS) in cross-sectional study of 216 healthy adults, aged 20-95. RESULTS: serum DHEAS levels declined, while total carnitine levels increased with age (P < 0.0001). Total and free carnitine and DHEAS levels were lower in women than men (P < 0.0001). Esterified/free (E/F) carnitine (inversely related to carnitine availability) increased with age in both sexes (P=0.012). CONCLUSION: reduced carnitine availability correlates with the age-related decline of DHEAS levels. These results are consistent with the hypothesis that decreased energy metabolism with age relates to DHEAS levels and carnitine availability.  相似文献   
9.
Although carnitine is present in a variety of foods, the mechanism of its absorption has not been previously studied in humans. We investigated the absorption of carnitine by studying uptake into human intestinal mucosal biopsy specimens. We found evidence of active transport in the duodenum and ileum, but not in the colon. We demonstrated that intracellular concentrations exceeded concentrations in the incubation media at steady states and that uptake against a concentration gradient was abolished by anoxia and by replacement of sodium ion with potassium. Studies of initial rate of uptake over a range of concentrations revealed a curve consistent with a two-component system: a saturable system with a KT of 558 microM and a linear component probably representing passive diffusion. Addition of D-carnitine and L-acetylcarnitine resulted in diminished uptake of L-carnitine, suggesting that these substrates utilize the same transport mechanism. These studies demonstrate the presence of an active intestinal transport system for L-carnitine in human intestinal mucosa.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号